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ABSTRACT
Background    Daisaikoto (DSKT), a classical tradition-
al Chinese herbal formula, has been used for treating 
digestive diseases for 1800 years in China. Therefore, 
in this study, we are going to investigate the effect of 
DSKT on diabetic fatty liver rats induced by a high-fat 
diet and streptozotocin (STZ), and the effects of DSKT 
on silent mating type information regulation 2 homolog 
1 (SIRT1) and nuclear factor kappa B (NF-kappaB).
Methods    Diabetic fatty liver rat model was selected 
to establish a high-fat diet and STZ. Sixty Wistar rats 
were divided into six groups (n = 10): control group, 
high-fat diet + STZ group, simvastatin treatment group, 
DSKT low dose, medial dose and high dose treatment 
groups. After 8 weeks of drug intervention, body and 
liver weights, blood chemistry, blood glucose and in-
sulin were examined. The expressions of sirtuin 1 and 
NF-kappaB in the liver were observed by RT-PCR and 
immunohistochemistry, respectively.
Results    A high-fat diet increased body, liver weights, 
and serum cholesterol concentrations. Intraperitoneal 
injection of STZ increased blood glucose and decreased 
body weights. DSKT improved them. Homeostasis mod-
el assessment-estimated insulin resistance (HOMA-IR) 
indices were increased in the high-fat diet groups. 
DSKT improved them too. In histological examinations 
of the liver, we observed a significant improvement after 
treatment. Immunostaining expression of NF-kappaB in 
the liver was improved by DSKT and simvastatin. The 
mRNA expressions of SIRT1 in the liver were increased 
by DSKT and simvastatin.
Conclusion    We have demonstrated that DSKT is ca-
pable of reversing dyslipidemia and insulin resistance 
induced by a high-fat diet and STZ. High dose DSKT 
reveals a stronger effect than simvastatin on the expres-
sions of SIRT1 and NF-kappaB. Furthermore, DSKT 
has shown a strong dose-depended protective effect on 
diabetic fatty liver. 
Key words    daisaikoto; diabetes; fatty liver; nuclear 
factor kappa B; silent mating type information regula-
tion 2 homolog 1 
Nonalcoholic fatty liver disease (NAFLD), the most 
common cause of chronic liver disease, shows an in-
creasing prevalence among adults.1 Recently, it has been 
proven that NAFLD is commonly associated with many 
symptoms of metabolic syndrome such as obesity, type 2 
diabetes mellitus (T2DM), dyslipidemia and insulin re-
sistance.2 The incidence of NAFLD is reported approx-
imately in the 20–30% range of the general population 
in various countries. However, it reaches nearly 70–75% 
in individuals with T2DM, and is almost certainly in-
creasing.3, 4 Accordingly, NAFLD seems to be linked to 
metabolic syndrome, and may precede T2DM develop-
ment.5 Compared with other patients, those with T2DM 
appear to have an increased risk of developing NAFLD 
and certainly have a higher risk of developing fibrosis 
and cirrhosis.3 Inhibition of excessive lipid synthesis and 
uptake is recognized to be an effective intervention for 
NAFLD, such as statins and fibrates.6–8 However, they 
cannot meet the demands for treatment due to differenc-
es in individuals, drug dependence and some potential 
side effects.9, 10
 Many cytokines are associated with the progression 
of NAFLD and T2DM, such as sirtuin 1 (SIRT1; silent 
mating type information regulation 2 homolog 1) and 
nuclear factor kappa B (NF-kappaB). SIRT1, an NA-
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D+-dependent deacetylase, is implicated in diverse cellu-
lar processes, including metabolism, inflammation and 
apoptosis.11–13 Increasing evidence shows that it may be 
involved in the development of NAFLD.14 Deng, XQ et 
al proved that SIRT1 protein levels are reduced in NA-
FLD induced by a high-fat diet in rats.15 It has the ability 
to activate or repress many non-histone proteins such as 
NF-kappaB.16 NF-kappaB, an oxidative stress sensitive 
transcription factor, plays an important role in regulation 
of the expression of many genes involved in inflamma-
tory responses, and NF-kappaB-induced cytokines have 
appeared widely in inflammatory diseases, including 
NAFLD and T2DM.17–19 However, research on SIRT1 
and NF-kappaB on daisaikoto (DSKT) treatment has 
not yet been included.
 DSKT (“Da-chai-hu-tang” in Chinese), a classical 
traditional Chinese herbal formula, has been used for 
treating digestive diseases for 1800 years in China. It 
was created by the well-known Chinese clinician Zhang 
Zhongjing in Eastern Han. Nowadays, it is used in Asian 
countries in patients with hypertension and associated 
symptoms,20 hyperlipidemia and diabetes mellitus.21 Ya-
mamoto et al. and Iizuka et al. have reported that DSKT 
has the effect of lowering hepatic triglyceride biosynthe-
sis in HepG2 human hepatocyte cells or experimental 
hypercholesterolemic models.22, 23 However, the effect of 
DSKT on diabetic fatty liver has not been proven and its 
effects on SIRT1 and NF-kappaB remain unclear.
 Therefore, in this study, we are going to investigate 
the effect of DSKT on diabetic fatty liver in rats induced 
by a high-fat diet and STZ, and the effects of DSKT on 
homeostasis of SIRT1 and NF-kappaB.
MATERIALS AND METHODS
Animals 
Eighty-five adult male Wistar rats (8 weeks, 200 ± 20 g, 
No. SCXK. Lu 20130003) were purchased from Shandong 
University of Traditional Chinese Medicine Laboratory An-
imal Center (Jinan, China). Rats were housed in individual 
cages under controlled environmental conditions (22 ± 2 °C 
relative humidity 40–60%, 12 h dark/light cycles, food and 
water ad libitum). Animals were used in the present study 
in accordance with the guidelines of the Shandong Univer-
sity of Traditional Chinese Medicine Institutional Animal 
Care and Use Committee. All studies were performed with 
approval from the committee (2013005-KY). 
Reagents
Simvastatin was purchased from Qilu Pharmaceutical 
(Jinan, China). Streptozotocin (STZ) was purchased from 
Sigma, St. Louis, MO. Anti-NF-kappaB and goat anti-rab-
bit antibody were obtained from Beijing Boosen Biological 
Technology (Beijing, China). Insulin ELISA Kit was pur-
chased from Nanjing Jiancheng Bioengineering Institute 
(Nanjing, China).
Composition and preparation of DSKT
DSKT consists of eight traditional Chinese herbs (Table 
1). Each of the herbs were purchased from Zhong-sheng 
Company of Traditional Crude Drugs (Qingdao, China), 
and carefully authenticated by Dr. Jun-Ying Shi, Shandong 
University of Traditional Chinese Medicine (Jinan, China). 
Voucher specimens (numbers were listed in Table 1) were 
deposited at the Herbarium of Shandong University of 
Traditional Chinese Medicine (SDU.TCM, Jinan, China). 
After drying, herbs were mixed in proportion, and 84 g of 
this material was combined with 300 mL of distilled water 
and boiled for 30 min at 100 °C. The extract was filtered, 
and the residual medicine was boiled in water following the 
same procedure once more. Finally, the pool of the extracts 
from two boilings and filterings was mixed and stored at 4 
°C.
Animal experiments
After 3 days adaptation, rats were randomly divided into 
six groups: control group (C, n = 10), high-fat diet + STZ 
group (H, n = 15), high-fat diet + STZ with simvastatin 
treated group (HS, n = 15), high-fat diet + STZ with low 
Table 1. Constituents of daisaikoto (DSKT) formulation
Components Part used Voucher specimens number Amount used (g)
Bupleuri Radix (Bupleurum falcatum L.) Root SDU.TCM 0062 15
Scutellariae Radix (Scutellaria baicalensis Georgi) Root SDU.TCM 0098 9
Rhei Rhizoma (Rheum palmatumL.) Rhizome SDU.TCM 0076 6
Aurantii Fructus Immaturus (Citrus aurantium L. var. daidai Makino) Fruit SDU.TCM 0203 9
Paeoniae Radix (Paeonia lactiflora Pallas) Root SDU.TCM 0046 9
Pinnelliae Tuber (Pinellia ternata Breit) Tuber SDU.TCM 0057 9
Zingiberis Rhizoma (Zingiber officinale Roscoe) Rhizome SDU.TCM 0132 15
Zizyphi Fructus (Zizyphus jujuba Mill. var. inermis Rehder) Fruit SDU.TCM 0080 12
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dose of DSKT treated group (HDL, n = 15), high-fat diet 
+ STZ with medial dose of DSKT treated group (HDM, n 
= 15), high-fat diet + STZ with high dose of DSKT treated 
group (HDH, n = 15). Group C was fed a standard rat diet. 
A high-fat diet was supplied for the other groups; it was 
made by adding 10% lard oil, 20% sucrose, 10% egg yolk 
powder and 0.5% cholic acid to the standard diet (purchased 
from Keao Xieli Feed, Beijing, China). After 6 weeks, STZ 
(30 mg/kg, 2% citrate buffer solution, pH 4.2) was supplied 
by intraperitioneal injection for rats in Groups H, HS, HDL, 
HDM, HDH. After 72 h of injection, rats with a level of 
fasting blood glucose over 11.1 mmol/L were regarded as 
successful models. Ten successful model rats in each group 
were selected for the following experiment. Rats in Groups 
C (n = 10) and H (n = 10) were treated with 0.9% saline by 
intragastric administration (10 mL/kg body weight per day); 
rats in Group HS (n = 10) were treated with simvastatin by 
intragastric administration (0.9 mg/10 mL/kg body weight 
per day); rats in Groups HDL (n = 10), HDM (n = 10) and 
HDH (n = 10) were treated with DSKT by intragastric ad-
ministration (3.75, 7.5, 15 g/10 mL/kg body weight per day, 
respectively). Dosages of drugs were calculated according 
to body surface area. The drug dosage for rats was equally 
proportionate to adult humans who take simvastatin (10 mg) 
and DSKT (84 g) per day, respectively. The body surface 
area conversion coefficient from humans to rats is 0.018. 
Dosage of drug for adult humans × 0.018 = dosage of drug 
for rats weighing 200 g. So the dosage of simvastatin for 
rats can be calculated according to the above formula: 10 
mg × 0.018 = 0.18 mg for rats weighing 200 g. This results 
in the dosage for rats weighing 1 kg as 0.9 mg. The dosage 
of DSKT for rats can also be calculated similarly according 
to the above formula: 84 g × 0.018 = 1.5 g for rats weighing 
200 g where the dosage for rats weighing 1 kg is 7.5 g, a 
medial dose; 3.75 g is defined as a low dose; 15 g is defined 
as a high dose. The drug intervention period is continued for 
8 weeks. The amount of feed for each rat was regulated to 
25 g/day and water was supplied ad libitum. Body weights 
were measured at 0, 6, 10 and 14 weeks. Blood glucose was 
measured at 0 week, 6 weeks, 6 weeks + 3 days, 8 weeks, 
10 weeks, 12 weeks and 14 weeks.
Sample collection
At the end of 14 weeks, rats in each group were sacrificed 
by collecting blood from the heart under pentobarbital an-
esthesia after fasting for 12 h. Liver tissues were removed, 
and then portions of the samples were stored in 10% for-
malin solution for hematoxylin and eosin (HE) staining. 
The remaining samples were immediately transferred into 
EP tubes containing 500 μL of RNA later, quickly frozen 
in liquid nitrogen, and stored at –80°C. Serum levels of TC 
(total cholesterol), HDL-C (high-density lipoprotein cho-
lesterol), LDL-C (low-density lipoprotein cholesterol), ALT 
(total bilirubin, alanine aminotransferase), ALP (alkaline 
phosphatase) and TG (triglyceride) levels were analyzed for 
rats using an auto analyzer at an accredited clinical labora-
tory (Affiliated Hospital of Shandong University of Tradi-
tional Chinese Medicine, Jinan, China). 
Insulin linked immunosorbent assay (ELISA)
Serum samples were applied for an ELISA of Insulin (Nan-
jing Jiancheng Bioengineering Institute, Nanjing, China) 
according to the manufacturer’s instructions. Insulin resis-
tance was evaluated according to the homeostasis model 
assessment-estimated insulin resistance (HOMA-IR) index. 
The HOMA-IR index was calculated according to the fol-
lowing equation reported by Matthews et al.24, 25 HOMA-IR 
index = fasting plasma insulin (mIU/L) × fasting plasma 
glucose (mmol/L)/22.5.
RT-PCR of SIRT1 
The tissues were quickly immersed in RNA later and stored 
at –80 °C. The total RNA was sequentially extracted using 
TRIZOL Reagent (Sigma-Aldrich, St. Louis, MO) accord-
ing to the manufacturer’s instructions. The RNA was treat-
ed with DNase (DNAfree, Ambion, Austin, TX) in order to 
remove contaminating genomic DNA, followed by phenol, 
chloroform extraction and ethanol precipitation. Total RNA 
was assessed for purity using the NanoDrop system. Total 
RNA was performed in a two-step procedure as described 
by Power SYBR Green PCR Master Mix kits (Applied 
Biosystems, Waltham, MA). Briefly, in the first step, cDNA 
was prepared from 500 ng RNA by reverse transcription 
in a final volume of 20 μL in a thermal cycler (Tgradient 
96, Whatman Biometra, Niedersachsen, Germany). The 
samples were incubated at 37 °C for 60 min and 95 °C for 
5 min. The cDNA were stored at –20 °C. The rat-specific 
primers for the genes of PPT, NEP and beta-actin were 
designed using Primer Premier 5.0 (Premier Biosoft, Palo 
Alto, CA). The primer sequences are shown in Table 2. 
Primers were synthesized by BioAsia (Shanghai, China). In 
the second step, quantitative real-time PCR was performed 
on a LightCycler apparatus (Roche Diag Diagnostics, 
Mannheim, Germany) using Power SYBR Green. PCR 
Master Mix kits (Applied Biosystems). The reaction was 
conducted with an initial denaturing at 95 °C for 10s, and 
then involved 40 cycles of 55 °C 10 s, 72 °C 15 s, and termi-
nated by a cooling step 30 s at 40 °C. A melting-curve anal-
ysis was performed to confirm the absence of primer di-
mers in specific PCR products. The efficiency of PCR was 
assessed with serial dilutions of a sample of cDNA from 
the normal control group. Each experiment was performed 
in duplicate and the data were analyzed using Light Cycler 
Software 4.0 (Roche Diagnostics, Basel, Switzerland). Be-
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ta-actin mRNA was used as the housekeeping gene, and all 
data are represented using the 2−ΔΔCT method .
Immunohistochemistry of NF-kappaB
The samples were fixed in 10% buffered formalin at 4 °C 
for 24–48 h. The samples were sectioned (4 μm thick) using 
a freezing microtome (ASpZr 35) and standard immunohis-
tochemical procedures were used to visualize NF-kappaB 
protein. Sections were washed 4 × 10 min in PBS (pH 7.4) at 
room temperature and were blocked with 10% normal goat 
serum. Sections were then incubated with anti- NF-kappaB 
(Beijing Bioss Biological Technology, Beijing, China) over-
night on a shaker at room temperature. Following washing 
(4 × 10 min) with PBS, sections were incubated for 2 h with 
goat anti-rabbit antibody. Finally, sections were washed (3 
× 10 min) in PBS, transferred onto gelatin-coated slides. 
Tissue processed without the primary NF-kappaB anti-
body served as a negative control. Adjacent sections were 
mounted onto plus-coated slides and stained using Neutral 
Red (0.5%), washed through a series of increasing alcohol 
concentrations, cleared with xylene and coverslipped with 
Neutral Blasam. 
Table 2. The sequence of each PCR primer
Gene Forward Reverse
Beta-actin 5’-GAGGGAAATCGTGCGTGAC-3’ 5’- GGACTCATCGTACTCCTGCTTG-3’
SIRT1 5’-CCAGAACAGTTTCATAGAGCC-3’ 5’TCTTACTTTCAGAGAAGACCCAATA-3’
PCR, polymerase chain reaction; SIRT1, sirtuin 1; silent mating type information regulation 2 homolog 1.
Table 3. Body and liver weights
Group C Group H Group HS Group HDL Group HDM Group HDH
Body weights (g)
0W 208.30 ± 11.95 206.10 ± 12.58 205.40 ± 11.69 208.80 ± 7.84 207.90 ± 11.29 207.70 ± 10.31
6W 355.60 ± 27.37 427.40 ± 27.59* 425.20 ± 26.60 422.70 ± 23.86 428.80 ± 17.25 430.40 ± 15.64
10W 398.60 ± 20.92 432.90 ± 31.07* 428.40 ± 22.10 446.30 ± 25.32 453.00 ± 25.28 469.50 ± 25.01†
14W 452.70 ± 15.30 388.90 ± 34.55* 390.10 ± 24.78 423.40 ± 21.43†‡ 428.90 ± 26.77†‡ 450.60 ± 27.92†‡§
Liver weights (g)
14W 14.79 ± 1.29 21.39 ± 2.52* 15.14 ± 1.69† 16.83 ± 1.29†‡ 16.41 ± 1.35† 15.02 ± 2.12†§
C: normal control group, standard rat diet for 14 weeks and treated with 0.9% saline 10 mL/kg every day (n = 10); H: high-fat diet + STZ 
group, high-fat diet for 14 weeks and treated with 0.9% saline 10 mL/kg every day (n = 15 at 0 week and n = 10 at 6, 10 and 14 weeks); 
HS: high-fat diet + STZ with simvastatin treated group, high-fat diet for 14 weeks and treated with simvastatin 0.9 mg/10 mL/kg every day (n 
= 15 at 0 week and n = 10 at 6, 10 and 14 weeks); HDL: high-fat diet + STZ with low dose of DSKT treated group, high-fat diet for 14 
weeks and treated with DSKT 3.75 g/10 mL/kg every day (n = 15 at 0 week and n = 10 at 6, 10 and 14 weeks); HDM: high-fat diet + STZ 
with medial dose of DSKT treated group, high-fat diet for 14 weeks and treated with DSKT 7.5 g/10 mL/kg every day (n = 15 at 0 week 
and n = 10 at 6, 10 and 14 weeks); HDH: high-fat diet + STZ with high dose of DSKT treated group, high-fat diet for 14 weeks and treated 
with DSKT 15 g/10 mL/kg every day (n = 15 at 0 week and n = 10 at 6, 10 and 14 weeks). *P < 0.05 vs. Group C, †P < 0.05 vs. Group H, 
‡P < 0.05 vs. Group HS, §P < 0.05 vs. Group HDL, ||P < 0.05 vs. Group HDM. Data are expressed as the means ± standard deviation. 
0W, 0 week; 6W, 6 weeks; 10W, 10 weeks; 14W, 14 weeks; DSKT, daisaikoto; STZ, streptozotocin.
 Five fields from every section were randomly se-
lected for examination using an Olympus CKX41-32PH 
microscope equipped with an imaging system (Olympus 
Optical, Tokyo, Japan). The distribution and staining of 
positive expression of liver tissue were observed under a 
400 x light microscope. The optical densities were mea-
sured by Image-Pro Plus v 6.0 software (Media Cyber-
netics, Rockville, MD). 
Statistical analysis
All statistical analyses were performed using SPSS 17.0 
software (SPSS, Chicago, IL). Data were expressed as 
mean ± S.E. Analysis of variance (ANOVA) was per-
formed when more than two groups were compared. 
Values of P < 0.05 were considered statistically signifi-
cant.
RESULTS
Body and liver weights
As Table 3 shows, there were no significant differences 
in the baseline of body weights at the beginning of the 
experiment. High-fat diet increased body weights in 
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Fig 1.
Fig. 1. Histological examination of the liver.
Fatty degeneration (steatosis) of the liver is observed in high-fat 
diet-fed groups (H, HS, HDL, HDM and HDH), but not in Group 
C in hematoxylin-eosin stained tissues. C: normal control group, 
standard rat diet for 14 weeks and treated with 0.9% saline 10 mL/
kg every day (n = 10); H: high-fat diet + STZ group, high-fat diet 
for 14 weeks and treated with 0.9% saline 10 mL/kg every day 
(n = 10); HS: high-fat diet + STZ with simvastatin treated group, 
high-fat diet for 14 weeks and treated with simvastatin 0.9 mg/10 
mL/kg every day (n = 10); HDL: high-fat diet + STZ with low 
dose of DSKT treated group, high-fat diet for 14 weeks and treated 
with DSKT 3.75 g/10 mL/kg every day (n = 10); HDM: high-fat 
diet + STZ with medial dose of DSKT treated group, high-fat diet 
for 14 weeks and treated with DSKT 7.5 g/10 mL/kg every day (n 
= 10); HDH: high-fat diet + STZ with high dose of DSKT treated 
group, high-fat diet for 14 weeks and treated with DSKT 15 g/10 
mL/kg every day (n = 10). Bars express 25 μm. DSKT, daisaikoto; 
STZ, streptozotocin.
Table 4. Blood chemistry and cholesterol concentrations
Group C Group H Group HS Group HDL Group HDM Group HDH
LDL-C
(mmol/L) 0.65 ± 0.08 2.09 ± 0.18* 0.96 ± 0.08† 1.88 ± 0.16†‡ 1.35 ± 0.14†‡§ 1.00 ± 0.10†§||
HDL-C
(mmol/L) 1.09 ± 0.22 0.54 ± 0.13* 0.91 ± 0.14† 0.67 ± 0.08†‡ 0.84 ± 0.09†§ 0.89 ± 0.14†§
TC
(mmol/L) 1.18 ± 0.26 2.49 ± 0.51* 1.32 ± 0.4† 1.98 ± 0.4†‡ 1.70 ± 0.44†‡ 1.38 ± 0.44†§
TG
(mmol/L) 0.8 ± 0.27 2.29 ± 0.42* 1.79 ± 0.34† 1.93 ± 0.49† 1.70 ± 0.32† 1.36 ± 0.43†‡§
ALT
(U/L) 39.11 ± 2.55 61.75 ± 5.18* 63.4 ± 6.96 55.14 ± 3.79†‡ 49.96 ± 3.48†‡§ 45.14 ± 4.00†‡§||
ALP
(U/L) 100.45 ± 9.95 154.69 ± 17.54* 168.8 ± 7.05† 127.38 ± 9.59†‡ 120.37 ± 10.33†‡ 112.47 ± 6.57†‡§
C: normal control group, standard rat diet for 14 weeks and treated with 0.9% saline 10 mL/kg every day (n = 10); H: high-fat diet + STZ 
group, high-fat diet for 14 weeks and treated with 0.9% saline 10 mL/kg every day (n = 10); HS: high-fat diet + STZ with simvastatin 
treated group, high-fat diet for 14 weeks and treated with simvastatin 0.9 mg/10 mL/kg every day (n = 10); HDL: high-fat diet + STZ with 
low dose of DSKT treated group, high-fat diet for 14 weeks and treated with DSKT 3.75 g/10 mL/kg every day (n = 10); HDM: high-
fat diet + STZ with medial dose of DSKT treated group, high-fat diet for 14 weeks and treated with DSKT 7.5 g/10 mL/kg every day (n 
= 10); HDH: high-fat diet + STZ with high dose of DSKT treated group, high-fat diet for 14 weeks and treated with DSKT 15 g/10 mL/
kg every day (n = 10). *P < 0.05 vs. Group C, †P < 0.05 vs. Group H, ‡P < 0.05 vs. Group HS, §P < 0.05 vs. Group HDL, ||P < 0.05 vs. 
Group HDM. Data are expressed as the means ± standard deviation. ALP, alkaline phosphatase; ALT, alanine aminotransferase; DSKT, 
daisaikoto; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; STZ, streptozotocin; TC, total cho-
lesterol; TG, triglyceride.
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Groups H, HS, HDL, HDM and HDH compared with 
Group C after 6 weeks (P < 0.05). Intraperitoneal injec-
tion of STZ decreased body weights in Group H com-
pared with Group C after 10 and 14 weeks (P < 0.05). 
DSKT ameliorated body weights in a dose dependent 
manner (P < 0.05). Liver weights were significantly 
higher in Group H than Group C after 14 weeks (P < 
0.05). Groups HS, HDL, HDM and HDH had decreased 
liver weights after 14 weeks (P < 0.05). Groups HS and 
HDH had a better effect than HDL (P < 0.05).
Histological examination of liver 
From hematoxylin-eosin staining we could find that the 
fatty degeneration (steatosis) of the liver was observed 
in the high-fat-diet-fed groups, but not in Group C. The 
tiny and large vacuoles as well as pleomorphic nuclei 
were more conspicuous in the treatment groups than in 
Group H (Fig. 1). Groups HS and HDH seem to show a 
better effect (× 400).
Blood chemistry and cholesterol concentrations
As Table 4 shows, the high-fat diet increased the concen-
trations of LDL-C, TC, TG, ALT, ALP and reduced the 
concentrations of HDL-C in Group H compared with 
Group C after 14 weeks in serum (P < 0.05). Compared 
with Group H, the concentrations of LDL-C, TC, TG, 
ALT and ALP decreased in Groups HS, HDL, HDM 
and HDH (P < 0.05), while the concentration of HDL-C 
had an opposite trend (P < 0.05). Groups HS and HDH 
had a better effect (P < 0.05). DSKT regulated blood 
chemistry and cholesterol concentrations in a dose de-
pendent manner (P < 0.05).
Blood glucose level
As shown in Fig. 2, there were no significant differences 
in the baseline of blood glucose level at the beginning 
of the experiment. The high fat diet increased blood 
glucose level slightly in Groups H, HS, HDL, HDM and 
HDH than in Group C after 6 weeks, but there were no 
statistical differences. Blood glucose increased greatly 
3 days after intraperitoneal injection of STZ in Groups 
H, HS, HDL, HDM and HDH. After treatment, blood 
glucose obviously decreased in Groups HDL, HDM and 
HDH compared with Group H, but not in Group HS af-
ter 8, 10, 12 and 14 weeks.
Insulin in serum and HOMA-IR Index
Insulin concentrations were increased in Group H com-
pared with Groups C and HDH after 14 weeks (Fig. 3, 
P < 0.05). HOMA-IR obviously increased in Groups 
H, HS, HDL, HDM and HDH compared with Group 
C (P < 0.05). After treatment, HOMA-IR decreased in 
Fig 2. 
Fig. 2. Blood glucose level.
Blood glucose increased greatly 3 days after intraperitioneal injec-
tion of STZ and decreased after treatment in Groups HDL, HDM 
and HDH. C: normal control group, standard rat diet for 14 weeks 
and treated with 0.9% saline 10 mL/kg every day (n = 10); H: 
high-fat diet + STZ group, high-fat diet for 14 weeks and treated 
with 0.9% saline 10 mL/kg every day (n = 15 at 0 and 6 weeks 
and n = 10 at 6 weeks + 3 days, 8 weeks, 10 weeks, 12weeks and 
14 weeks; HS: high-fat diet + STZ with simvastatin treated group, 
high-fat diet for 14 weeks and treated with simvastatin 0.9 mg/10 
mL/kg every day (n = 15 at 0 and 6 weeks and n = 10 at 6 weeks 
+ 3 days, 8 weeks, 10 weeks, 12weeks and 14 weeks); HDL: high-
fat diet + STZ with low dose of DSKT treated group, high-fat diet 
for 14 weeks and treated with DSKT 3.75 g/10 mL/kg every day (n 
= 15 at 0 and 6 weeks and n = 10 at 6 weeks + 3 days, 8 weeks, 10 
weeks, 12weeks and 14 weeks); HDM: high-fat diet + STZ with 
medial dose of DSKT treated group, high-fat diet for 14 weeks 
and treated with DSKT 7.5 g/10 mL/kg every day (n = 15 at 0 
and 6 weeks and n = 10 at 6 weeks + 3 days, 8 weeks, 10 weeks, 
12weeks and 14 weeks); HDH: high-fat diet + STZ with high dose 
of DSKT treated group, high-fat diet for 14 weeks and treated with 
DSKT 15 g/10 mL/kg every day (n = 15 at 0 and 6 weeks and 
n = 10 at 6 weeks + 3 days, 8 weeks, 10 weeks, 12weeks and 14 
weeks). 0W, 0 week; 2W, 2 weeks; 4W, 4weeks; 6W, 6weeks; 8W, 
8 weeks; 10W, 10 weeks; 12W, 12 weeks; 14W, 14 weeks. 6 weeks 
+ 3 days means 3 days after intraperitioneal injection of STZ. 
DSKT, daisaikoto; STZ, streptozotocin.
Groups HS, HDL, HDM and HDH (P < 0.05). DSKT 
decreased HOMA-IR in a dose dependent manner (P < 
0.05).
SIRT1 mRNA expression in the liver
As Fig. 4 shows, SIRT1 mRNA expression in the liver in 
Group H was significantly decreased compared to that in 
other groups (P < 0.05). Groups HS, HDL, HDM and HDH 
increased SIRT1 mRNA expression in the liver to a various 
degree (P < 0.05). Group HDH had a better effect. DSKT 
increased SIRT1 mRNA expression in the liver in a dose 
dependent manner (P < 0.05).
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Fig 3.
Fig. 3. Insulin in serum and HOMA-IR Index.
C: normal control group, standard rat diet for 14 weeks and treated 
with 0.9% saline 10 mL/kg every day (n = 10); H: high-fat diet 
+ STZ group, high-fat diet for 14 weeks and treated with 0.9% 
saline 10 mL/kg every day (n = 10); HS: high-fat diet + STZ with 
simvastatin treated group, high-fat diet for 14 weeks and treated 
with simvastatin 0.9 mg/10 mL/kg every day (n = 10); HDL: high-
fat diet + STZ with low dose of DSKT treated group, high-fat diet 
for 14 weeks and treated with DSKT 3.75 g/10 mL/kg every day 
(n = 10); HDM: high-fat diet + STZ with medial dose of DSKT 
treated group, high-fat diet for 14 weeks and treated with DSKT 
7.5 g/10 mL/kg every day (n = 10); HDH: high-fat diet + STZ with 
high dose of DSKT treated group, high-fat diet for 14 weeks and 
treated with DSKT 15 g/10 mL/kg every day (n = 10). HOMA-IR 
index = fasting plasma insulin (mIU/L) × fasting plasma glucose 
(mmol/L)/22.5. *P < 0.05 vs. Group C, †P < 0.05 vs. Group H, 
‡P < 0.05 vs. Group HS, §P < 0.05 vs. Group HDL, ||P < 0.05 vs. 
Group HDM. DSKT, daisaikoto; HOMA-IR, Homeostasis model 
assessment-estimated insulin resistance; STZ, streptozotocin.
Fig 4.
Fig. 4. Changes of mRNA expression of SIRT1 in liver after 14 
weeks.
Levels of SIRT1 against beta-actin mRNA expression are shown 
in the above histogram. C: normal control group, standard rat diet 
for 14 weeks and treated with 0.9% saline 10 mL/kg every day (n 
= 10); H: high-fat diet + STZ group, high-fat diet for 14 weeks and 
treated with 0.9% saline 10 mL/kg every day (n = 10); HS: high-
fat diet + STZ with simvastatin treated group, high-fat diet for 14 
weeks and treated with simvastatin 0.9 mg/10 mL/kg every day (n 
= 10); HDL: high-fat diet + STZ with low dose of DSKT treated 
group, high-fat diet for 14 weeks and treated with DSKT 3.75 g/10 
mL/kg every day (n = 10); HDM: high-fat diet + STZ with medial 
dose of DSKT treated group, high-fat diet for 14 weeks and treat-
ed with DSKT 7.5 g/10 mL/kg every day (n = 10); HDH: high-fat 
diet + STZ with high dose of DSKT treated group, high-fat diet 
for 14 weeks and treated with DSKT 15 g/10 mL/kg every day (n 
= 10). *P < 0.05 vs. Group C, †P < 0.05 vs. Group H, ‡P < 0.05 vs. 
Group HS, §P < 0.05 vs. Group HDL, ||P < 0.05 vs. Group HDM. 
DSKT, daisaikoto; SIRT1, sirtuin 1, silent mating type informa-
tion regulation 2 homolog 1; STZ, streptozotocin.
NF-kappaB immunostaining expression in liver
As shown in Fig. 5A, after 14 weeks, NF-kappaB im-
munostaining (Yellow-brown deposits indicate positive 
staining) was seldom found in hepatic cells in Group C. 
Significantly positive NF-kappaB immunostaining was 
observed in Group H and mainly localized in cell cyto-
plasm and the nucleus. Positive NF-kappaB immunos-
taining was also observed in Groups HS, HDL, HDM 
and HDH, but less than in Group H (× 400). Mean opti-
cal density values of NF-kappaB are shown in Fig. 5B. 
The photographs generated quantitatively analyzed the 
optical density of NF-kappaB by Image - Pro Plus. After 
treatment, the expressions in Groups HS, HDL, HDM 
and HDH decreased more than in Group H. Also, Group 
HDH was significantly lower compared with Groups 
HS, HDL and HDM (P < 0.05).
DISCUSSION
NAFLD is commonly associated with many symptoms 
of metabolic syndrome such as obesity and T2DM.2 
Patients with T2DM appear to have an increased risk 
of developing NAFLD and certainly have a higher risk 
of developing fibrosis and cirrhosis.3 Individuals always 
present simultaneously with characteristics of high blood 
glucose, insulin resistance, hyperlipidemia and fatty liv-
er. It has been reported that the abnormal serum levels of 
HDL-C and LDL-C are associated with NAFLD.26 And 
NAFLD with T2DM patients always show up-regulated 
TC and LDL-C and down-regulated HDL-C levels.27, 28 
Statins, one kind of lipid-lowering drug, can inhibit cho-
lesterol synthesis. They can definitely decrease LDL-C 
and increase HDL-C. However, there is a risk that they 
sometimes are instrumental in causing rhabdomyolysis 
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Fig 5.
A
B
Fig. 5. NF-kappaB immunostaining expression in liver after 14 weeks.
A: Immunohistochemistry expression of NF-kappaB in liver. Arrows show the positive NF-kappaB immunostaining. B: Mean optical 
density values of NF-kappaB. The photographs generated were quantitatively analyzed the optical density of NF-kappaB with Image - 
Pro Plus. C: normal control group, standard rat diet for 14 weeks and treated with 0.9% saline 10 mL/kg every day (n = 10); H: high-fat 
diet + STZ group, high-fat diet for 14 weeks and treated with 0.9% saline 10 mL/kg every day (n = 10); HS: high-fat diet + STZ with sim-
vastatin treated group, high-fat diet for 14 weeks and treated with simvastatin 0.9 mg/10 mL/kg every day (n = 10); HDL: high-fat diet + 
STZ with low dose of DSKT treated group, high-fat diet for 14 weeks and treated with DSKT 3.75 g/10 mL/kg every day (n = 10); HDM: 
high-fat diet + STZ with medial dose of DSKT treated group, high-fat diet for 14 weeks and treated with DSKT 7.5 g/10 mL/kg every day 
(n = 10); HDH: high-fat diet + STZ with high dose of DSKT treated group, high-fat diet for 14 weeks and treated with DSKT 15 g/10 mL/
kg every day (n = 10). *P < 0.05 vs. Group C, †P < 0.05 vs. Group H, ‡P < 0.05 vs. Group HS, §P < 0.05 vs. Group HDL, ||P < 0.05 vs. 
Group HDM. Bars express 25 μm. DSKT, daisaikoto; NF-kappaB, nuclear factor kappa B; STZ, streptozotocin.
A
B
Fig 5. 
B 
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and hepatitis. Traditional Chinese medicine is always 
considered a safe way to harmonize the abnormal serum 
levels of HDL-C and LDL-C, to improve high blood 
glucose as well as minimize side effects. In a previous 
study of ours, we found fatty liver, up-regulated TC and 
LDL-C as well as down-regulated HDL-C in high-cho-
lesterol diet rats.29, 30 In this experiment, fatty steatosis 
and high blood glucose were observed after adminis-
tration of a high-fat diet and STZ in Group H. Body 
weights decreasing after intraperitoneal injection of STZ 
may be associated with the elevated blood glucose; it 
could be ameliorated by DSKT. DSKT and simvastatin 
could decrease the concentrations of LDL-C and TC 
and increase HDL-C. However, ALT and ALP concen-
trations in Group HS were significantly elevated than in 
the DSKT groups. The reason may be that DSKT has 
fewer side effects than simvastatin. On the other hand, 
DSKT can reduce the high blood glucose levels, while 
simvastatin does not have very stable effects and cannot 
improve high blood glucose effectively. Insulin secretion 
increasing in Group H compared with Group C may be 
a compensatory response against the increased blood 
glucose and impaired insulin function. HOMA-IR in-
creased obviously in Groups H, HS, HDL, HDM and 
HDH compared with Group C. This shows that the body 
is not sensitive to insulin, and leads to difficulty in de-
creased blood glucose. DSKT also obviously inhibits in-
sulin resistance. Furthermore, DSKT has shown a strong 
dose-dependent effect on diabetic fatty liver. 
 SIRT1, an NAD+-dependent deacetylase, is im-
plicated in diverse cellular processes, including me-
tabolism, inflammation and apoptosis.11–13 Increasing 
evidence has shown that it may be involved in the devel-
opment of NAFLD.14 Deng, XQ et al have proven that 
SIRT1 protein levels are reduced in NAFLD induced 
by high-fat diet in rats.15 SIRT1 target multiple cellular 
proteins take part in metabolic homeostasis, oxidative 
stress as well as in inflammation, such as NF-kappaB.31 
It is reported that hepatic SIRT1 is a key regulator of 
lipid homeostasis, in particular fatty acid oxidation. Loss 
of SIRT1 in hepatocytes can lead to a decrease in fatty 
acid oxidation, resulting in the development of hepatic 
steatosis and inflammation on high-fat diet mice.32 In 
this study, hepatic mitochondrial SIRT1 expression was 
significantly reduced in Group H, as previously shown 
by others. DSKT tended to increase hepatic SIRT1 
expression, explaining in part its beneficial effect with 
respect to high-fat diet induced disorders.
 An additional mechanism related to DSKT could 
elicit beneficial effects through NF-kappaB. As is well 
known, long-time intake of a high-fat diet could result 
in low-grade inflammation. This inflammation state is 
characterized by the activation of the NF-kappaB path-
way.33 NF-kappaB, an oxidative stress sensitive tran-
scription factor, plays an important role in regulation of 
the expression of many genes involved in inflammatory 
responses, and NF-kappaB-induced cytokines appear 
widely in inflammatory diseases, including NAFLD and 
T2DM.17–19 Andrade JM et al proved that NF-kappaB 
was increased in high-fat diet mice.34 Group H in our 
study displayed higher hepatic NF-kappaB activity as 
compared to Group C. According to Morgan,35 this ac-
tivation could have been triggered, at least partially, by 
reactive oxygen species (ROS), which occurs in excess 
in the liver. However, Group HDH showed the strongest 
effect to prevent liver NF-kappaB activation and this 
reveals a dose-depend trend. The antioxidant effects of 
a high dose of DSKT likely contributed to the inhibition 
of NF-kappaB activation. 
 In conclusion, we have demonstrated that DSKT is 
capable of reversing blood lipid and blood glucose disor-
ders induced by high-fat diet and STZ. DSKT improves 
insulin resistance as well as liver oxidative and inflam-
matory status, which are closely linked to the develop-
ment of NAFLD with T2DM. Similarly, the antioxidant 
properties of DSKT contribute, at least partially, to 
improving the inflammatory status of the liver. Molec-
ular targets involved in these beneficial effects include 
NF-kappaB inhibition and the involvement of SIRT1. 
These results may be a guide for clinical use in the treat-
ment of T2DM with fatty liver.
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